Oesophageal disease patients can have similar symptoms — but their diseases may be different. This means tests aren't always conclusive and treatment isn't always effective:
Our solutions help you objectively evaluate the root cause of oesophageal motility disorders and GORD:
Download and access the EndoflipTM Impedance Planimetry System Protocole & Interpretation white paper
The right treatment for each patient depends on many factors. We provide resources to aide patients understand their conditions and empower themselves
Learn how our comprehensive portfolio can help you care for patients across the care continuum — from GORD to Barrett's oesophagus.
1. Laine, Goldmann et al. In the clinic: gastroesophageal reflux disease. Annals of Internal Medicine. 2008 Aug 5; ITC2: 1-16.
2. Kahrilas PJ. Gastroesophageal reflux disease. N Engl J Med. 2008; 359: 1700-7.
3. Ronkainen et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005; 129: 1825-1831.
4. Kawamura O, Hosaka H, Shimoyama Y et al. Evaluation of proton pump inhibitor resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring. Digestion. 2015;91(1):19-25.
5. Herregods, T. V. K., et al. Patients with refractory reflux symptoms often do not have GERD: Neurogastroenterology & Motility. 2015; 27(9): 1267-1273.
6. Ahuja NK, Agnihotri A, Lynch KL, et al. Esophageal distensibility measurement: impact on clinical management and procedure length. Diseases Of The Esophagus: Official Journal Of The International Society For Diseases Of The Esophagus. 2017;30(8):1-8.
7. Triadafilopoulos G, Zikos T, Regalia K, et al. Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms. Digestive Diseases And Sciences. 2018;63(10):2673-2680. doi:10.1007/s10620-018-5183-4.